(Q37594794)

21 August 2017

1 reference

title

Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships (English)

1 reference

21 August 2017

1 reference

5

Johannes M F G Aerts

1 reference

21 August 2017

1

Carla E M Hollak

1 reference

21 August 2017

4

Stephan Vom Dahl

1 reference

21 August 2017

3

Laura van Dussen

1 reference

21 August 2017

2

Maaike de Fost

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

16

1 reference

21 August 2017

page(s)

2641-2652

1 reference

METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Gaucher disease: complexity in a "simple" disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Gaucher's disease: clinical features and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Prevalence of lysosomal storage disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

An avascular crisis in Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Occurrence of Parkinson's syndrome in type I Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Imiglucerase and its use for the treatment of Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and S

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Isofagomine induced stabilization of glucocerebrosidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Effective cell and gene therapy in a murine model of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

A less costly regimen of alglucerase to treat Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Clinically relevant therapeutic endpoints in type I Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Enzyme replacement therapy for Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Therapeutic goals in the treatment of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Quality of life assessment in adults with type 1 Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Individualization of long-term enzyme replacement therapy for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Withdrawal of enzyme replacement therapy in Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Cessation of enzyme replacement therapy in Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903270520

10.1517/14656560903270520

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference